VİTAMİN D KANSERDEN SORUMLU MU? DOES VITAMIN D CAUSE TO CANCER?

Öz

 Özet

Vitamin D, kemik metabolizması haricinde birçok hastalık ve kansere karşı potansiyel koruyucu etkileri vardır. Hücre proliferasyonu, apopitozu, inflamasyon ve angiogenez üzerinden kanser insidansı, progresyonu ve bazı kanser tiplerinde mortaliteye karşı vitamin D’nin koruyucu etiklerine ait veriler giderek artmaktadır. Meme kanseri, prostat kanseri, gastrointestinal kanserler açısından  epidemiyolojik veriler ve preklinik bulgular Vitamin D’nin kanser gelişimi ve progresyonundaki rollerini desteklemektedir. 

Anahtar kelimeler: Vitamin D, kanser, dehidrokolekalsiferol

 DOES VITAMIN D CAUSE TO CANCER?

Vitamin D has a potential protective effects against cancer and some diseases except bone metabolism. Data  about the protective  effects of  vitamin D against cancer incidence, progression and mortality of different types  which are due to cell proliferatiton, apaptozis, inflammation and angiogenesis, have increased. The epidemiologycal data and preclinical findings support the role of vitamin D at cancer development and progression in relation to breast, prostat and colorectal cancers.

Key words:Vitamin D, cancer, dehidrocolecalsiferol

Anahtar Kelimeler

• Vitamin D, kanser, dehidrokolekalsiferol

References

1. Mocellin S. Vitamin D and cancer: Deciphering the truth. Biochimica et Biophysica Acta 1816 (2011) 172–178
2. Krishnan AV, Feldman D, Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D.Annu. Rev. Pharmacol. Toxicol. 2011;51:311-36.
3. Peterlik M, Cross HS, Vitamin D and calcium insufficiency-related chronic diseases: molecular and cellular pathophysiology. Eur. J. Clin. Nutr. 63 (2009) 1377–1386.
4. Garland F, Gorham ED, Mohr SB, Garland FC, Vitamin D for cancer prevention: global perspective.Ann. Epidemiol. 19 (2009) 468–483
5. Krishnan AV, Trump DL, Johnson CS, Feldman D, The role of vitamin D in cancer prevention and treatment. Endocrinol. Metab. Clin. North Am. 39 (2010) 401–418.
6. Deeb KK, Trump DL, Johnson CS, Vitamin D signalling pathways in cancer: potential for anticancer therapeutics.Nat. Rev. Cancer 7 (2007) 684–700.
7. Campbell MJ, Elstner E, Holden S, Uskokovic M, Koeffler HP, Inhibition of proliferation of prostate cancer cells by a 19-nor-hexafluoride vitamin D3 analogue involves the induction of p21waf1, p27kip1 and E-cadherin.J. Mol. Endocrinol.19 (1997) 15–27.
8. Holick MF,The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med 29(6) (2008): 361–8.

9. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2011) ;96(7):1911–30.
10. Adams JS and Hewison M, Update in Vitamin D. J Clin Endocrinol Metab (2010);95(2): 471–478.
11. Holick MF, Vitamin D Deficiency. N Engl J Med 357: 266–281.Metab (2007);95(2): 471–478.
12. Rosen CJ, Adams JS, Bikle DD, Black DM, Demay MB, et al. The nonskeletal effects of vitamin D: an Endocrine Society Scientific statement. Endocr Rev (2012);33(3): 456–92.
13. Giovannucci E, Expanding roles of vitamin D. J Clin Endocrinol Metab 2009;94: 418–420.
14. Garland CF, Gorham ED, Mohr SB, Garland FC,Vitamin D for cancer prevention: global perspective. Ann Epidemiol (2009);19: 468–483.
15. Hossein-Nezhad A, Spira A, Holick MF. Influence of vitamin d status and vitamin D3 supplementation on genome wide expression of white blood cells: a randomized double-blind clinical trial.PLoS One. 2013;8(3):e58725. doi:10.1371/journal.pone.0058725
16. Yang ES, Burnstein KL, Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 278 (2003) 46862–46868.
17. Verlinden L, Verstuyf A, Convents R, Marcelis S, Van Camp M, Bouillon R, Action of 1,25(OH)2D3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells.Mol.Cell. Endocrinol. 142 (1998) 57–65.
18. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J, Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery.Mol. Endocrinol. 15 (2001) 1370–1380.
19. Boyle BJ, Zhao XY, Cohen P, Feldman D, Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J. Urol. 165 (2001) 1319–1324.
20. Peng L, Malloy PJ, Feldman D, Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter.Mol. Endocrinol. 18 (2004) 1109–1119.
21. Palmer HG, Sanchez-Carbayo M, Ordonez-Moran P, Larriba MJ, Cordon-Cardo C, Munoz A, Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells.Cancer Res. 63 (2003) 7799–7806.
22. Li P, Li C, Zhao X, Zhang X, Nicosia SV, Bai W, p27(Kip1) stabilization and G(1) arrest by 1,25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclin-dependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase.J. Biol. Chem. 279 (2004)25260–25267
23. Ma Y, Yu WD, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS, 1alpha,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model.Mol. Cancer Ther. 7 (2008) 3047–3055.
24. Blutt SE, McDonnell TJ, Polek TC, Weigel NL, Endocrinology 141 (2000) 10–17.
25. Narvaez CJ, Welsh J, Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells.J. Biol. Chem. 276 (2001) 9101–9107
26. Jiang F, Bao J, Li P, Nicosia SV, Bai W, Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase.J. Biol. Chem. 279 (2004) 53213–53221.
27. Hoyer-Hansen M, Nordbrandt SP, Jaattela M, Autophagy as a basis for the health-promoting effects of vitamin D.Trends Mol. Med. 16 (2010) 295–302.
28. Pan L, Matloob AF, Du J, Pan H, Dong Z, Zhao J, Feng Y, Zhong Y, Huang B, Lu J, Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A /sodium butyrate-induced and 5-aza-2'-deoxycytidine-induced PTEN upregulation.FEBS J. 277 (2010) 989–999.
29. Mantell DJ, Owens PE, Bundred NJ, Mawer EB, Canfield AE, Circ. Res. 87(2000) 214–220.
30. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ, Mol. 1alpha,25-dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells.Cancer Ther. 6 (2007) 1433–1439.
31. Chung I, Han G, Seshadri M, Gillard BM, Yu WD, Foster BA, Trump DL, Johnson CS, Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo.Cancer Res. 69 (2009) 967–975.
32. Bao BY, Yao J, Lee YF, 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis.Carcinogenesis 27 (2006) 1883–1893.
33. Aparna R, Subhashini J, Roy KR, Reddy GS, Robinson M, Uskokovic MR, Venkateswara Reddy G, Reddanna P, Selective inhibition of cyclooxygenase-2 (COX-2) by 1alpha,25-dihydroxy-16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J. Cell. Biochem. 104 (2008) 1832–1842.
34. Agarwal S, Reddy GV, Reddanna P, Eicosanoids in inflammation and cancer: the role of COX-2. Expert Rev. Clin. Immunol. 5 (2009)145–165.
35. Chung I, Wong MK, Flynn G, Yu WD, Johnson CS, Trump DL, Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells.Cancer Res. 66 (2006) 8565–8573.
36. Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D, Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene.Nat. Genet. 25 (2000) 144–146.
37. King AN, Beer DG, Christensen PJ, Simpson RU, Ramnath N, The vitamin D/CYP24A1 story in cancer.Anticancer Agents Med Chem. 10 (2010) 213–224.
38. Koli K, Keski-Oja J, 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells.Cell Growth Differ. 11 (2000) 221–229.
39. Gonzalez-Sancho JM, Alvarez-Dolado M, Munoz A, 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expression in mammary epithelial cells. FEBS Lett. 426 (1998) 225–228.
40. Sung V, Feldman D, 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Mol. Cell. Endocrinol. 164 (2000) 133–143
41. Mantovani A, . Molecular pathways linking inflammation and cancer.Curr. Mol. Med. 10 (2010) 369–373
42. Krishnan AV, Shinghal R, Raghavachari N, Brooks JD, Peehl DM, Feldman D, Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays.Prostate 59 (2004) 243–251.
43. Van Waes C, Nuclear factor-kappaB in development, prevention, and therapy of cancer.Clin. Cancer Res. 13 (2007) 1076–1082.,
44. Sun J, Kong J, Duan Y, Szeto FL, Liao A, Madara JL, Li YC, . Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor.Am. J. Physiol. Endocrinol. Metab. 291 (2006) E315–E322
45. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O, Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling Mol.Immunol. 44 (2007) 3625–3632.
46. Uitterlinden AG, Fang Y, van Meurs JB, van Leeuwen H, Pols HA, Vitamin D receptor gene polymorphisms in relation to Vitamin D related disease states.J. Steroid Biochem. Mol. Biol. 89–90 (2004) 187–193.
47. Mocellin S, Nitti D, Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis.Cancer 113 (2008) 2398–2407.
48. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalizch K, Affleck P, Leake S, Haynes S, Karpavicius B, Marsden J, Gerry E, Bale L, Bertram C, Field H, Barth JH, Silva Idos S, Swerdlow A, Kanetsky PA, Barrett JH, Bishop DT, Bishop JA,Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data.Eur. J. Cancer 45 (2009) 3271–3281.
49. Raimondi S, Johansson H, Maisonneuve P, Gandini S, Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk.Carcinogenesis 30 (2009) 1170–1180.
50. Tang C, Chen N, Wu M, Yuan H, Du Y, Fok1 polymorphism of vitamin D receptor gene contributes to breast cancer susceptibility: a meta-analysis.Breast Cancer Res. Treat. 117 (2009) 391–399.
51. Gandini S, Raimondi S, Gnagnarella P, Dore JF, Maisonneuve P, Testori A, Vitamin D and skin cancer: a meta-analysis.Eur. J. Cancer 45 (2009) 634–641
52. Gorham ED, Garland CF, Garland FC, Grant WB, Mohr SB, Lipkin M, Newmark HL, Giovannucci E, Wei M, Holick MF, Optimal vitamin D status for colorectal cancer prevention: a quantitative meta analysis.Am. J. Prev.Med. 32 (2007) 210–216
53. Yin L, Raum E, Haug U, Arndt V, Brenner H, Meta-analysis of longitudinal studies: Serum vitamin D and prostate cancer risk.Cancer Epidemiol. 33 (2009) 435–445.
54. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H, . Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment. Pharmacol. Ther.30 (2009) 113–125
55. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P, Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma.Int. J. Cancer 2011;128(6):1414-24.
56. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H, Meta-analysis: serum vitamin D and breast cancer risk.Eur. J. Cancer 46 (2010) 2196–2205.
57. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H, Meta-analysis of vitamin D, calcium and the prevention of breast cancer.Breast Cancer Res. Treat. 121 (2010) 469–477.
58. Toner CD, Davis CD, Milner JA, The vitamin D and cancer conundrum: aiming at a moving target.J. Am. Diet. Assoc. 110 (2010) 1492–1500.
59. Jacobs ET,Martinez ME, Jurutka PW, Cancer Epidemiol. Biomarkers Prev. 20(2011) 585–590.
60. Chen L, Davey Smith G, Evans DM, Cox A, Lawlor DA, Donovan J, Yuan W, Day IN, Martin RM, Lane A, Rodriguez S, Davis M, Zuccolo L, Collin SM, Hamdy F, Neal D, Lewis SJ, Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol. Biomarkers Prev. 18 (2009)2874–2881..
61. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, Kukalizch K, Whitaker L, Jackson S, Gerry E, Nolan C, Bertram C, Marsden J, Elder DE, Barrett JH, Bishop DT, Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J. Clin. Oncol. 27 (2009) 5439–5444.
62. Ng K, Meyerhardt JA, Wu K, Feskanich D, Hollis BW, Giovannucci EL, Fuchs CS, Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer.J. Clin. Oncol. 26 (2008) 2984–2991.
63. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK,Durazo-Arvizu RA, Gallagher JC, RGallo L, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.J. Clin. Endocrinol. Metab. 2011; 96(1): 53–58.
64. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichtenstein A, Patel K, Raman G, Tatsioni A, Terasawa T, Trikalinos , Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep)(2009) 1–420.
65. Muindi JR, Potter DM, Peng Y, Johnson CS, Trump DL, Pharmacokinetics of liquid calcitriol formulation in advanced solid tumor patients: comparison with caplet formulation.Cancer Chemother.Pharmacol. 56 (2005) 492–496.
66. Beer TM, Javle MM, Ryan CW, Garzotto M, Lam GN, Wong A, Henner WD, Johnson CS, Trump DL, Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer.Cancer Chemother. Pharmacol. 59 (2007) 581–587.
67. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, J. Clin. Oncol. 25 (2007) 669–674.
68. Attia S, Eickhoff J, Wilding G, McNeel D, Blank J, Ahuja H, Jumonville A, Eastman M, Shevrin D, Glode M, Alberti D, Staab MJ, Horvath D, Straus J, Marnocha R, Liu G, Clin. Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer. Cancer Res. 14 (2008) 2437–2443.
69. Chadha MK, Tian L, Mashtare T, Payne V, Silliman C, Levine E, Wong M, Johnson C, Trump DL, Phase 2 trial of weekly intravenous 1,25 dihydroxy cholecalciferol (calcitriol) in combination with dexamethasone for castration-resistant prostate cancer.Cancer 116 (2010) 2132–2139.
70. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP, Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial.Am. J. Clin. Nutr. 85 (2007) 1586–1591.
71. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA, Calcium plus vitamin D supplementation and the risk of breast cancer.J. Natl. Cancer Inst. 100 (2008) 1581–1591.
72. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Sharma S, Stefanick ML, Van Horn L, Wallace RB, Whitlock E, Bassford T, Beresford SA, Black HR, Bonds DE, Brzyski RG, Caan B, Chlebowski RT, Cochrane B, Garland C, Gass M, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia, Hubbell FA, Jackson RD, Johnson KC, Judd H, Kooperberg CL, Kuller LH, LaCroix AZ, Lane DS, Langer RD, Lasser NL, Lewis CE, Limacher MC, Manson JE, Engl N. J. Med. 354 (2006) 684–696.
73. Ding EL, Mehta S, Fawzi WW, Giovannucci EL, Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: reanalysis of Women's Health Initiative randomized trial.Int. J. Cancer 122 (2008) 1690–1694.
74. Trivedi DP, Doll R, Khaw KT, Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial.BMJ 326 (2003) 469.
75. IARC. Vitamin D and Cancer. IARC Working Group Reports Vol.5, International Agency for research on Cancer, Lyon, 25 November 2008.